Hims & Hers Threatens Hone Health
Hone Health
The threat from Hims & Hers is not just bigger marketing spend, it is that a scaled telehealth machine can move into hormone care once the workflow gets standardized enough. Hone has built its business around recurring labs, consults, and dosage changes that make testosterone therapy stickier and higher value than ED pills. Hims now has the revenue base, category expansion playbook, and a live testosterone partnership that make that moat narrower over time.
-
Hone still has a real workflow advantage today. Its core plan bundles blood testing, physician consults, and ongoing monitoring, with patients paying about $225 per month on average. That is a more operationally heavy service than the classic Hims and Ro model built around async intake and drug fulfillment for simpler categories like ED and hair loss.
-
What makes Hims the biggest risk is scale plus adjacency. Hims reported $2.35B of 2025 revenue, launched menopause care in 2025, and announced in September 2025 that KYZATREX oral testosterone would be offered through its platform. That means it is no longer just a broad telehealth storefront, it is actively assembling the pieces for hormone therapy.
-
Ro is the clearest proof that mass market telehealth can climb into more complex care when economics justify it. Ro built in home phlebotomy, diagnostics, pharmacies, and a subscription obesity program to support GLP-1s. That same pattern matters for testosterone, where the winner is not the best landing page, it is the operator that can handle repeat labs, follow ups, and refill management at scale.
The market is heading toward a split between low cost telehealth distribution and higher touch hormone management. If Hims and Ro keep building lab, pharmacy, and care management infrastructure, testosterone care will start to look less like a protected niche and more like the next category that scaled consumer telehealth platforms can absorb.